Leerink Partnrs Issues Optimistic Estimate for BEAM Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Beam Therapeutics in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($1.06) per share for the quarter, up from their previous forecast of ($1.23). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics' Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.36) EPS and FY2026 earnings at ($4.33) EPS.

Several other research analysts have also commented on the company. Bank of America upgraded Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 target price for the company in a research report on Friday, March 28th. Royal Bank of Canada lifted their target price on Beam Therapeutics from $24.00 to $26.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Beam Therapeutics in a research report on Monday, April 7th. Wells Fargo & Company reduced their price objective on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, Jones Trading upgraded Beam Therapeutics from a "hold" rating to a "buy" rating and set a $34.00 price objective for the company in a research report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $48.75.

Beam Therapeutics Stock Up 4.8%

Shares of BEAM traded up $0.83 during mid-day trading on Friday, hitting $18.24. The stock had a trading volume of 2,231,538 shares, compared to its average volume of 1,435,975. The company has a market cap of $1.83 billion, a PE ratio of -10.36 and a beta of 2.35. The company's fifty day simple moving average is $20.07 and its two-hundred day simple moving average is $24.36. Beam Therapeutics has a fifty-two week low of $13.53 and a fifty-two week high of $35.25.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.13). The firm had revenue of $7.47 million during the quarter, compared to analyst estimates of $14.69 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. Beam Therapeutics's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.21) EPS.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Nuveen LLC bought a new stake in shares of Beam Therapeutics in the 1st quarter worth $3,904,000. Invesco Ltd. raised its stake in shares of Beam Therapeutics by 33.2% in the 1st quarter. Invesco Ltd. now owns 88,291 shares of the company's stock worth $1,724,000 after buying an additional 22,026 shares in the last quarter. Benjamin Edwards Inc. raised its stake in shares of Beam Therapeutics by 8.0% in the 1st quarter. Benjamin Edwards Inc. now owns 26,314 shares of the company's stock worth $514,000 after buying an additional 1,956 shares in the last quarter. Swiss National Bank raised its stake in shares of Beam Therapeutics by 25.3% in the 1st quarter. Swiss National Bank now owns 172,600 shares of the company's stock worth $3,371,000 after buying an additional 34,800 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Beam Therapeutics by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,492 shares of the company's stock worth $205,000 after buying an additional 879 shares in the last quarter. Institutional investors and hedge funds own 99.68% of the company's stock.

Insiders Place Their Bets

In other Beam Therapeutics news, CEO John M. Evans sold 30,663 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total transaction of $562,666.05. Following the completion of the transaction, the chief executive officer now owns 986,249 shares in the company, valued at approximately $18,097,669.15. The trade was a 3.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Giuseppe Ciaramella sold 7,434 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $136,413.90. Following the transaction, the president now owns 190,216 shares of the company's stock, valued at $3,490,463.60. This trade represents a 3.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,771 shares of company stock worth $803,198. 4.20% of the stock is owned by company insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.